Clinical and haemodynamic effects of oral metoprolol therapy in dilated cardiomyopathy.
The clinical and haemodynamic effects of oral metoprolol therapy were assessed in thirty patients of dilated cardiomyopathy, aged 14-58 (33 +/- 10.9) years. After baseline haemodynamic study, metoprolol was administered in a dose of 25-100 mg/day (mean 87.0 +/- 25.1 mg/day). Before start of therapy, 13 patients were in NYHA symptom class IV, 14 were in NYHA class III and 3 were in NYHA class II. Symptomatic improvement was seen on oral metoprolol therapy in all patients except one. Six months after therapy 13 patients were asymptomatic, 16 were in NYHA class II, while 1 patient continued to be in NYHA class III. Repeat haemodynamic study in 15 patients done at a mean of 5.7 months showed a significant fall in the right ventricular end diastolic pressure (from 9.1 +/- 4.4 to 5.7 +/- 2.9 mm Hg, p less than 0.01), mean pulmonary artery pressure (from 32.3 +/- 13 to 24.5 +/- 10.3 mmHg, P less than 0.01) and mean pulmonary capillary pressure (from 23.3 +/- 10.3 mmHg to 14.7 +/- 7.4 mmHg, P less than 0.01). The left ventricular ejection fraction increased from 18.8 +/- 6.3 to 24.0 +/- 7.3 per cent, (P less than 0.05), while no significant change was observed in the cardiac index (2.43 +/- 0.47 to 2.66 +/- 0.83 L/min/m2, p = NS). These data suggest improvement in diastolic and systolic left ventricular function after metoprolol therapy.